Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hip stem could mean better bone preservation for younger patients

NCT ID NCT07600632

Disease control Sponsor: Istituto Ortopedico Rizzoli Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well a short, bone-friendly stem works for total hip replacement when done through a front-of-hip incision. Researchers will follow 400 adults with hip arthritis for at least two years to check implant survival, complications, pain, and recovery. The goal is to see if this stem design helps preserve bone and improves outcomes, especially for younger and more active people.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
short femoral stem implant (cementless, hydroxyapatite-coated)
What this could lead to
If successful, this could confirm that short stems are a safe and effective option for hip replacement, especially for younger, active patients, potentially preserving bone and improving recovery.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. Previous reports have shown mixed outcomes, including implant loosening or bone changes, particularly in active patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes consecutively treated adult patients undergoing primary total hip arthroplasty performed through a direct anterior approach with a cementless femoral component, at the Department of Orthopaedics, Trauma Surgery, and Hip and Knee Arthroplasty and Revision Surgery of the IRCCS Istituto Ortopedico Rizzoli. Patients will be included from 2022 (retrospective cohort) to 2027 (prospective cohort).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of primary hip osteoarthritis or osteonecrosis * Minimally invasive direct anterior approach * Cementless femoral component * Minimum follow-up of 2 years * Patient willingness to participate in the study with written informed consent * Age over 18 years * Male or female patients Exclusion Criteria: * Other diagnoses of secondary hip osteoarthritis * Non-anterior surgical approach * Cemented or other types of components * Patient unwillingness to participate in the study * Inadequate clinical and radiological documentation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hip arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteoarthritis, hip osteonecrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hip arthritis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IRCCS Istituto Ortopedico Rizzoli

    RECRUITING

    Bologna, 40136, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.